139 related articles for article (PubMed ID: 38382744)
1. Use of Antihistamines During Omalizumab Therapy in Chronic Urticaria in the Routine Clinical Practice. A 48-Patient Observational Trial.
Menéndez-Sánchez M; Pérez-Fernández E; López-Estebaranz JL; Gómez-de la Fuente E
Actas Dermosifiliogr; 2024 Jun; 115(6):636-638. PubMed ID: 38382744
[No Abstract] [Full Text] [Related]
2. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
[No Abstract] [Full Text] [Related]
3. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
Di Leo E; Calogiuri G; Macchia L; Nettis E
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
[No Abstract] [Full Text] [Related]
4. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
[No Abstract] [Full Text] [Related]
5. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU.
Ertaş R; Hawro T; Altrichter S; Özyurt K; Erol K; Ketenci Ertaş Ş; Maurer M
Allergy; 2020 Feb; 75(2):468-470. PubMed ID: 31469912
[No Abstract] [Full Text] [Related]
6. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
7. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
8. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
9. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
Abe N; Bohgaki M; Kasahara H
Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
[TBL] [Abstract][Full Text] [Related]
10. Chronic Spontaneous Urticaria: An Update on the Evaluation and Management.
Joshi SR; Anstey KM; Khan DA
Immunol Allergy Clin North Am; 2024 Aug; 44(3):503-515. PubMed ID: 38937012
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
12. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
[TBL] [Abstract][Full Text] [Related]
15. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab.
Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A
Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
Dortas Junior S; Azizi G; Valle S
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.
Gastaminza G; Azofra J; Nunez-Cordoba JM; Baeza ML; Echechipía S; Gaig P; García BE; Labrador-Horrillo M; Sala-Cunill A; Brescó MS; Beristain A; Quiñones D; Donado CD; Zubeldia JM; Ferrer M
J Allergy Clin Immunol Pract; 2019; 7(5):1599-1609.e1. PubMed ID: 30654196
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
Ayhan E; Öztürk M; An İ; Bekçİbaşi M
Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
[No Abstract] [Full Text] [Related]
20. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
